Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 10,000 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.98, for a total value of $279,800.00. Following the completion of the transaction, the chief executive officer owned 362,152 shares of the company’s stock, valued at approximately $10,133,012.96. The trade was a 2.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Claire Mazumdar also recently made the following trade(s):

• On Friday, July 10th, Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.42, for a total value of $284,200.00.

Bicara Therapeutics Stock Up 3.7%

Shares of BCAX stock opened at $24.63 on Thursday. The business’s fifty day moving average is $26.00 and its 200 day moving average is $21.74. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -7.95 and a beta of -0.75. Bicara Therapeutics Inc. has a twelve month low of $10.30 and a twelve month high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, meeting the consensus estimate of ($0.82). Equities research analysts expect that Bicara Therapeutics Inc. will post -3.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc boosted its stake in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Bicara Therapeutics during the fourth quarter valued at $45,000. Larson Financial Group LLC lifted its holdings in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after purchasing an additional 3,595 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Bicara Therapeutics by 385.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after buying an additional 4,585 shares during the last quarter.

Analyst Ratings Changes

BCAX has been the topic of several research reports. Wall Street Zen raised shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th. Guggenheim began coverage on Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 price objective for the company. Wells Fargo & Company lifted their price objective on Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, The Goldman Sachs Group raised their price target on Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bicara Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $32.73.

Bicara Therapeutics News Roundup

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara reported second-quarter loss of $0.82 per share, matching consensus expectations. More importantly, management said enrollment in its pivotal cancer study remains on track for 2026, providing a potentially important clinical catalyst. Bicara Therapeutics stock gains as pivotal trial enrollment advances
• Positive Sentiment: Analyst sentiment improved following the quarterly update. BTIG Research raised its price target from $28 to $39 and maintained a Buy rating, while other analysts also lifted forecasts. The broader consensus remains a Moderate Buy with an average target of approximately $32.73. Analysts raise Bicara Therapeutics forecasts
• Positive Sentiment: Wedbush reiterated that Bicara’s cancer study is on track for 2026 enrollment, supporting the view that the company could deliver meaningful development milestones in the near term. Bicara Therapeutics cancer study remains on track
• Neutral Sentiment: Analyst views remain mixed. Wells Fargo raised its target from $16 to $23 but kept an Equal Weight rating, while other firms maintain more bullish targets. Bicara also announced strategic leadership transitions as it enters its next execution phase. Wells Fargo price-target update
• Negative Sentiment: CEO Claire Mazumdar, COO Ryan Cohlhepp and CFO Ivan Hyep sold a combined 41,250 shares for about $1.15 million. The transactions were made under pre-arranged Rule 10b5-1 plans, and the executives retained substantial stakes, which reduces—but does not eliminate—the negative signal from the insider selling. Bicara insider transaction filings

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.